| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
MRK
Merck & Company
|
Aug 05, 2026 | BUY |
Strong Buy
+0.4% avg upside
43 analysts
|
$150.00
16.74% Upside
|
+0.2% | · |
|
LLY
Eli Lilly & Co
|
Aug 03, 2026 | BUY |
Strong Buy
-11.7% avg upside
48 analysts
|
$1400.00
18.08% Upside
|
+5.7% | · |
|
BMY
Bristol-Myers Squibb
|
Jul 31, 2026 | BUY |
Buy
-5.8% avg upside
42 analysts
|
$75.00
15.95% Upside
|
-0.9% | · |
|
AMGN
Amgen
|
Jul 29, 2026 | HOLD |
Buy
-23.6% avg upside
57 analysts
|
$360.00
12.32% Downside
|
+6.0% | · |
|
ABBV
AbbVie
|
Jul 29, 2026 | BUY |
Strong Buy
-3.2% avg upside
46 analysts
|
$300.00
21.99% Upside
|
-6.6% | · |
|
GILD
Gilead Sciences
|
Jul 29, 2026 | HOLD |
Strong Buy
-10.7% avg upside
66 analysts
|
$145.00
8.90% Upside
|
+0.4% | · |
|
BIIB
Biogen
|
Jul 29, 2026 | HOLD |
Strong Buy
+21.6% avg upside
52 analysts
|
$200.00
3.89% Downside
|
-1.4% | · |
|
PFE
Pfizer
|
Jun 15, 2026 | SELL |
Buy
+25.0% avg upside
45 analysts
|
$25.00
6.59% Downside
|
-4.7% | · |
|
CYTK
Cytokinetics
|
Apr 06, 2026 | BUY |
Strong Buy
+16.7% avg upside
36 analysts
|
$95.00
23.78% Upside
|
+18.2% | · |
|
GSK
GlaxoSmithKline
|
Jan 06, 2026 | SELL |
Hold
-17.6% avg upside
19 analysts
|
— | -6.6% | · |
|
RHHBY
Roche Holding
|
Jan 06, 2026 | BUY |
Strong Buy
+102.5% avg upside
14 analysts
|
— | +14.4% | · |
|
SNY
Sanofi
|
Jan 06, 2026 | HOLD |
Strong Buy
+69.7% avg upside
20 analysts
|
— | -4.8% | · |
|
NVS
Novartis
|
Jan 06, 2026 | HOLD |
Hold
-14.5% avg upside
24 analysts
|
— | +13.2% | · |
|
CH:ROP
Roche Holding AG
|
Sep 24, 2025 | HOLD |
Buy
-8.8% avg upside
23 analysts
|
$275.00
25.08% Downside
|
+47.4% | · |
|
FR:SAN
Sanofi
|
Aug 12, 2025 | BUY |
Strong Buy
+30.2% avg upside
30 analysts
|
$105.00
39.49% Upside
|
-5.7% | · |
|
GB:GSK
GlaxoSmithKline
|
Aug 12, 2025 | HOLD |
Hold
-1.7% avg upside
25 analysts
|
$1450.00
26.03% Downside
|
+35.0% | · |
|
CH:SDZ
Sandoz Group Ltd
|
Aug 08, 2025 | BUY |
Buy
-7.2% avg upside
11 analysts
|
$55.00
24.52% Downside
|
+56.6% | · |
|
GB:0QIU
Novo Nordisk
|
Aug 04, 2025 | HOLD |
Hold
+35.0% avg upside
29 analysts
|
$375.00
22.83% Upside
|
· | · |
|
GB:AZN
AstraZeneca
|
Jul 30, 2025 | BUY |
Strong Buy
+22.2% avg upside
26 analysts
|
$14000.00
17.75% Upside
|
+11.6% | · |
|
NL:LKFT
Galapagos
|
Jul 29, 2025 | SELL |
Sell
+124.5% avg upside
16 analysts
|
$22.00
5.69% Downside
|
+16.7% | · |
|
CH:NOVN
Novartis AG
|
Jul 21, 2025 | SELL |
Buy
-12.0% avg upside
32 analysts
|
$90.00
28.62% Downside
|
-40.2% | · |
|
DE:BAYN
Bayer
|
Jun 27, 2025 | HOLD |
Strong Buy
+5.2% avg upside
30 analysts
|
$25.00
49.76% Downside
|
+84.6% | · |
|
GB:HIK
Hikma Pharmaceuticals
|
Apr 25, 2025 | HOLD |
Buy
+38.8% avg upside
8 analysts
|
$2000.00
19.23% Upside
|
-28.5% | · |
|
GB:0MGB
Genmab A/S
|
Apr 15, 2025 | BUY |
Buy
+4.7% avg upside
23 analysts
|
$2100.00
5.12% Upside
|
+42.5% | · |
|
DE:MRK
Merck KGaA
|
Oct 29, 2024 | BUY |
Buy
-4.6% avg upside
33 analysts
|
$195.00
35.80% Upside
|
-24.2% | · |
|
GB:0QW0
arGEN X
|
Jun 21, 2023 | BUY |
Strong Buy
-20.7% avg upside
24 analysts
|
$430.00
44.32% Downside
|
+1.1% | · |
|
ES:GRF
Grifols
|
Nov 21, 2022 | SELL |
Buy
+45.1% avg upside
12 analysts
|
$9.00
11.45% Downside
|
-25.4% | · |
|
FR:IPN
Ipsen
|
Nov 25, 2021 | SELL |
Hold
-23.1% avg upside
17 analysts
|
$75.00
53.50% Downside
|
-25.1% | · |
|
GB:0NZT
UCB SA
|
Oct 15, 2021 | HOLD |
Buy
-1.7% avg upside
19 analysts
|
$90.00
60.26% Downside
|
-24.3% | · |
|
LKFT
Lakefront Biotherapeutics
|
Jan 19, 2021 | HOLD |
Buy
+292.7% avg upside
24 analysts
|
$125.00
362.95% Upside
|
-49.2% | · |
|
HK:0013
HUTCHMED (China)
|
Aug 28, 2020 | HOLD |
Buy
+507.6% avg upside
6 analysts
|
$52.82
171.23% Upside
|
· | · |
|
RVLPQ
RVL Pharmaceuticals
|
Apr 25, 2019 | BUY |
Strong Buy
+624999900.0% avg upside
6 analysts
|
$14.00
1399999899.99% Upside
|
· | · |
|
GRFS
Grifols SA
|
Jun 01, 2018 | BUY |
Buy
+209.1% avg upside
12 analysts
|
— | -19.0% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.